0001104659-22-085864.txt : 20220804 0001104659-22-085864.hdr.sgml : 20220804 20220804070339 ACCESSION NUMBER: 0001104659-22-085864 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 221134594 BUSINESS ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: BLOCKS A & B, PORTWAY BUILDING STREET 2: GRANTA PARK, GREAT ABINGTON CITY: CAMBRIDGE STATE: X0 ZIP: CB21 6GS FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 8-K 1 tm2222487d1_8k.htm FORM 8-K
0001761612 false 00-0000000 true 0001761612 2022-08-04 2022-08-04 0001761612 us-gaap:CommonStockMember 2022-08-04 2022-08-04 0001761612 bcyc:AmericanDepositarySharesMember 2022-08-04 2022-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

August 4, 2022

Date of Report (Date of earliest event reported)

 

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

 

England and Wales   001-38916   Not applicable

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Blocks A & B, Portway Building,
Granta Park, Great Abington, Cambridge
United Kingdom

CB21 6GS
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: +44 1223 261503

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

Emerging growth company    ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

  

Item 2.02. Results of Operations and Financial Condition

 

On August 4, 2022, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2022 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01Other Events

 

Also on August 4, 2022, the Company posted an updated corporate presentation on the Company’s website. To access the presentation, investors should visit the “Presentation and Events” section of the Company’s website at investors.bicycletherapeutics.com.

 

The information furnished under this Item 8.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

 

Item 9.01Financial Statements and Exhibits

 

(d)       Exhibits

 

Exhibit No.   Description
99.1   Press Release issued August 4, 2022 regarding financial results and business highlights
104  

Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 4, 2022 Bicycle Therapeutics plc
   
  By: /s/ Lee Kalowski
  Name: Lee Kalowski
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2222487d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

 

-    Continued clinical progress across pipeline, including dosing of the first patient in expansion

cohorts of Phase I/II study of BT5528

 

-    Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to

Bicycle in Q3

 

-     Cash and cash equivalents of $372.8 million as of June 30, 2022, excludes $9.8 million UK R&D
tax credit received in July and Genentech payment; expected financial runway into 2025

 

CAMBRIDGE, England, & BOSTON, August 4, 2022 – Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

 

“We are pleased with the progress of our wholly owned clinical oncology pipeline of Bicycle Toxin Conjugate, or BTC™, programs and Bicycle tumor-targeted immune cell agonist®, or Bicycle TICA™, programs,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “In the second quarter, we initiated the expansion cohorts of our Phase I/II study of BT5528, and development of BT8009 and BT7480 remains on track as these programs advance in their respective clinical trials.”

 

“In addition, we were delighted to announce the second expansion of our immuno-oncology collaboration with Genentech last month, highlighting the potential of the platform beyond our BTCs and Bicycle TICAs,” Dr Lee continued. “We are pleased to have a strong balance sheet which helps support the advancement of our programs and which we anticipate provides a financial runway into 2025.”

 

Second Quarter 2022 and Recent Highlights

 

·Announced First Patient Dosed in the Expansion Cohorts of Phase I/II Trial of BT5528. In June 2022, Bicycle announced that the first patient was dosed in the expansion cohorts of the Phase I/II study of BT5528, Bicycle’s second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2. Up to 56 patients will be enrolled in the initial expansion cohorts, with the ability to further expand enrollment based on the results from these cohorts. Bicycle intends to provide completed results of the dose escalation portion of the clinical trial during the third quarter of 2022.

 

·Announced Expansion of Genentech Immuno-Oncology Collaboration. In July 2022, Bicycle announced that Genentech exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. This expansion represented the second option exercised by Genentech under the terms of the original February 2020 agreement and triggered a $10 million payment to Bicycle, which is expected to be received in the third quarter of 2022.

 

 

 

 

·Presented Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In June 2022, Bicycle presented a Trials in Progress poster highlighting the Phase I/II clinical trial of BT7480, a novel, fully synthetic Bicycle TICA™ targeting Nectin-4 and agonizing CD137.

 

·Announced Interim BT8009 Phase I Clinical Trial Results at the 2022 American Association for Cancer Research (AACR) Annual Meeting. In April 2022, Bicycle announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4. As of March 7, 2022, 37 patients have been dosed in the Phase I/II trial of BT8009. A total of 12 response evaluable urothelial cancer (UC) patients have been dosed in monotherapy cohorts of 2.5mg/m2 and 5.0mg/m2 weekly in the ongoing trial. Four response evaluable UC patients were dosed at 2.5mg/m2 weekly, with one patient observed to have tumor reductions constituting a confirmed partial response (PR) and two patients observed to have stable disease (SD). Eight response evaluable UC patients were dosed at 5.0mg/m2 weekly, with four patients observed to have a confirmed complete response (CR) or PR, including one patient with a CR and three patients with a PR, and two patients with SD, reflecting a 50% overall response rate and 75% disease control rate. As of March 7, 2022, the median duration of response had not yet been reached in either the 2.5 mg/m2 or 5.0mg/m2 cohort, with four of the five responders in these cohorts still on therapy after at least 24 weeks.

 

Exploration of additional doses and frequencies continues, and Bicycle intends to provide further updates this year.

 

Financial Results

 

·Cash and cash equivalents were $372.8 million as of June 30, 2022, compared to $438.7 million as of December 31, 2021. The decrease in cash is primarily due to cash used in operating activities.

 

·Research and development expenses were $19.9 million for the three months ended June 30, 2022, compared to $11.7 million for the three months ended June 30, 2021. The increase in expense of $8.2 million was primarily due to increased clinical program expenses for BT5528 and BT8009, Bicycle TICA program development expenses, as well as increased personnel-related expenses, including $1.6 million of incremental non-cash share-based compensation expenses, and increased facilities-related expenses.

 

·General and administrative expenses were $11.8 million for the three months ended June 30, 2022, compared to $7.3 million for the three months ended June 30, 2021. The increase of $4.5 million for the three months ended June 30, 2022 as compared to the same period in the prior year was primarily due to an increase in personnel-related expenses, including $1.5 million of incremental non-cash share-based compensation expense, and an unfavorable effect of foreign exchange rates.

 

·Net loss was $26.8 million, or $(0.90) basic and diluted net loss per share, for the three months ended June 30, 2022, compared to net loss of $17.9 million, or $(0.74) basic and diluted net loss per share, for the three months ended June 30, 2021.

 

 

 

 

About Bicycle Therapeutics

 

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1- MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts. For more information, visit bicycletherapeutics.com.

 

Forward Looking Statements

 

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s anticipated advancement of its product candidates, including BT5528, BT8009 and BT7480; the anticipated dosing in and progression of Bicycle’s clinical trials; the availability of data from clinical trials; the therapeutic potential for Bicycles in oncology and other applications; Bicycle’s plans to expand its discovery efforts and early development pipeline; and Bicycle’s expected financial runway. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to clinical trial site initiation, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials and clinical development of Bicycle’s product candidates; the risk that Bicycle may not realize the intended benefits of its technology; availability and timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; the risk that Bicycle’s projections regarding its expected financial runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 5, 2022, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

 

 

 

 

Bicycle Therapeutics plc

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

 

    Three Months Ended  Six Months Ended 
   June 30,   June 30, 
   2022   2021   2022   2021 
Collaboration revenues  $4,378   $1,785   $8,238   $3,593 
Operating expenses:                    
Research and development   19,854    11,722    34,138    21,415 
General and administrative   11,824    7,340    28,783    15,479 
Total operating expenses   31,678    19,062    62,921    36,894 
Loss from operations   (27,300)   (17,277)   (54,683)   (33,301)
Other income (expense):                    
Interest income   908    23    1,126    38 
Interest expense   (883)   (819)   (1,701)   (1,341)
Total other income (expense), net   25    (796)   (575)   (1,303)
Net loss before income tax provision   (27,275)   (18,073)   (55,258)   (34,604)
Benefit from income taxes   (447)   (160)   (866)   (500)
Net loss  $(26,828)  $(17,913)  $(54,392)  $(34,104)
Net loss per share, basic and diluted  $(0.90)  $(0.74)  $(1.84)  $(1.48)
Weighted average ordinary shares outstanding, basic and diluted   29,648,564    24,052,168    29,626,974    23,047,745 

 

Balance Sheets Data

(In thousands)

(Unaudited)

 

   June 30,   December 31, 
   2022   2021 
Cash and cash equivalents  $372,769   $438,680 
Working capital   367,152    422,317 
Total assets   445,482    479,792 
Total shareholders’ equity   311,392    346,254 

 

Investors:

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com

617 203-8300

 

Media:

Argot Partners

Sarah Sutton

bicycle@argotpartners.com

212-600-1902

 

 

 

 EX-101.SCH 3 bcyc-20220804.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bcyc-20220804_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bcyc-20220804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] American Depositary Shares [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] American Depositary Shares EX-101.PRE 6 bcyc-20220804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2222487d1_ex99-1imag01.jpg GRAPHIC begin 644 tm2222487d1_ex99-1imag01.jpg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htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 04, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2022
Entity File Number 001-38916
Entity Registrant Name Bicycle Therapeutics plc
Entity Central Index Key 0001761612
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code X0
Entity Address, Address Line One Blocks A & B, Portway Building
Entity Address, Address Line Two Granta Park, Great Abington
Entity Address, City or Town Cambridge
Entity Address, Country GB
Entity Address, Postal Zip Code CB21 6GS
City Area Code +44
Local Phone Number 1223 261503
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Title of 12(b) Security Ordinary shares, nominal value £0.01 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share
Trading Symbol BCYC
Security Exchange Name NASDAQ

XML 9 tm2222487d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001761612 2022-08-04 2022-08-04 0001761612 us-gaap:CommonStockMember 2022-08-04 2022-08-04 0001761612 bcyc:AmericanDepositarySharesMember 2022-08-04 2022-08-04 iso4217:USD shares iso4217:USD shares 0001761612 false 00-0000000 true 8-K 2022-08-04 Bicycle Therapeutics plc X0 001-38916 Blocks A & B, Portway Building Granta Park, Great Abington Cambridge GB CB21 6GS +44 1223 261503 false false false false Ordinary shares, nominal value £0.01 per share NASDAQ American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share BCYC NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bicycletherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2222487d1_8k.htm bcyc-20220804.xsd bcyc-20220804_def.xml bcyc-20220804_lab.xml bcyc-20220804_pre.xml tm2222487d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2222487d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "bcyc-20220804_def.xml" ] }, "inline": { "local": [ "tm2222487d1_8k.htm" ] }, "labelLink": { "local": [ "bcyc-20220804_lab.xml" ] }, "presentationLink": { "local": [ "bcyc-20220804_pre.xml" ] }, "schema": { "local": [ "bcyc-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 1, "memberStandard": 1, "nsprefix": "bcyc", "nsuri": "http://bicycletherapeutics.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222487d1_8k.htm", "contextRef": "From2022-08-04to2022-08-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://bicycletherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222487d1_8k.htm", "contextRef": "From2022-08-04to2022-08-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "bcyc_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://bicycletherapeutics.com/20220804", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bicycletherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-085864-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-085864-xbrl.zip M4$L#!!0 ( '(X!%6C?L1]R@, !H. 1 8F-Y8RTR,#(R,#@P-"YX MUQ1A,Y[DA)FOHE X(K"2,28 #0 MDOKU68"D)$NR;DGXA,LY![O@[F+;;V=I0IY :2Y%QVO4ZAX!P63,Q:CC?1KX MUX.;;M **W,@T2\ ;A0GA>2BUFA%Q/J-5G]?([C'[/-5N0S^CUQ?35K,^_C$!F3_ MTL&'9O00___8/WOX;S(SZ=]G43QY/YQ/,O9(S_L\$9>SQ^;YX/*Z.+*MV1A2 M2O!G"-WQK'^E>]-63:I1T*S7&\&7^][ X;P"&,X2+B;;X(VKJZO [5;0#>0L M4DDEW0KL=D0U+)1QE^_ P9/C8+PBKX(B@VGT'Y5NA?!917T!C6W:3N!W8;]QUA<<".Q^GB$QQVO&%I!E'>2,0RY MX.[<,D4;Q+<)F5MW<>@H[6 =O"*1:X@?Q!LWSA1HY#E'>KA0$DO("R1&$Y8G MQW&6IFREE O5A2VOL$K#/@R)2]_0QD?'T]P64*]<&RL8=CP;(G[UI[ZB:S4, MG0IBI7>DK[OY]=LH#ZXDJ&(;*AOE!45D!LIPC/^5&E*8SHVE_[-R#+'G:(\$ M/\/EA$;'NHP42'ZAKSVK_U.=Q$@ZULGGP?>+/+U='++J;ED:@F5M*.?K]:.- MCDMEB-BH2;O>FN*5[$GFI'90[,RO>+Y=\AM-+,RUF8Z7EAYCQ/(:CC.BXIU@ MQ(LOWC8+],L$._2+X:%'[WP]=QZ_E1E 8G2UXB^U3C%G\ZW] 7N^;#OLI%:OX(;:5^H'@V-Z) MG6K(GM H.R[7M]B*_?4Z!<49%;>02O+0ZS-7,8?W1,2Y\IYAEU>,:]ZSC"6*>6B:R"U M2+R)',6YR2WZG9(Y-LN%'$=(X5H[**X+A]\!4$L#!!0 ( '(X!%6O"!QB M^@@ '!I 5 8F-Y8RTR,#(R,#@P-%]D968N>&ULU5U=<]LV%GWOS/X' M5GV6]>%XMW'C=A39[FB:Q*[EIMN^>" 2DC"& "T VM*_7X ?,BGBDE1J0V0> M')DZ ,X]!P1Q28#^\,MF1;TG+"3A[*(S..EW/,Q\'A"VN.C\,>V.IN/)I.-) MA5B *&?XHL-XYY>?__6=I_]]^+[;]:X)IL&Y=\G][H3-^4_>%[3"Y]ZOF&&! M%!<_>5\1#]7S (N_KB;[.I= M*K66Y[W>\_/S">-/Z)F+1WGB\U6]"J<*J5#N:NMO^LF_N/@'2MCCN?DQ0Q)[ M6B\FSS>27'1,NTFSSZ]&T*+2 W,T'3-DY[*9U=S?K;0.T*9,%GO?C++)245)TA+:W;@KKFD/=P;![.CC9R*"3^A2)+3C%=WCNF?^UT;M69\3?^KKG M+'7'6N-0$3^RN6=PO3'7W5B3CFI8"CR_Z,PT7#A8UOM15"#^YJ M(4SU-+278'K6"MZ>]ZZQ;L!7B!Q(NEC: >.HI>X*KV;&[H/HYHN^/5=$Z6$, MHP)OSXMQ-3J46EK&:9_$YZP/$T;,F/=)_YKCC3=*7X)PD#(W M%7[#$*6(,N62:\W ZYH+4ZAI*?TQ1B:,4DZ4^SDBU(S*7!05E&GHIDJF1\SP..CV!\DX_$-R^,%<%+$AH\/'$_U1ILU0-,,T:OPA M =NPO29POT>SEPY6PCO![7-^Z0,CD;)/.E#-LS3NM><^9TKWFBL:M:9[/EZ8 M#RFSN>"K2D$3\7AI!%F%-9&.QT6 A9[7]5^X4"YQ<-%1(K2$?!2;QA1)>3.? M*NX_CC:D3D\K%GE5\ZP7VBJS\AX 1D&Q6CP[KCM9HI?)A1NRQ89]53^*25SR)!AO\V./ PL]%_+E/0:^D_'NV]V+8H.,N[TV,;QU8JSB.WG9%H) M^K8/?0/;\A-(UET0AL9TND< 2 MU-F4*B_T8#O/&Z%X3>[@^/4J5Q2)_9,%?^H%F$1GP/_>F8_=^&,\-$&D$M%-QUU0Y0.)M4BCC:AF M#LYHW#LR8BQ$]$Y?=D2%$5ED*_0O$(9D?^=>]M]#)!06=%M'^3UP*\2W<8;T M/SO"!$8@G>,8N>H8L(]NA0-6TI %_W9OP72)*37/#!&K=184\:VP : -&?&? MXQIQ]60F$#J\^E[LBK3.CCQSR)$?W3MRJY-!'NBX1 TO]L"M<,'&&=+__;'T MOV)!7?43:(NTSS(N>[S@6OIK(GU$8X[7^ICMJ4$FF *\%1;86;_ZS;5_;,-? M&(G:)NS +;(@SQDTP&&F/ Z%R-$K'84@=*,M*"4->N P-[YBBJBM6=3V)03N M-VO8/JK1FEO)@EH[3(AC8NFM$J;,VKTRO?/(%FAN(0SJ[C 1CLF-=0@"T0D+ M\.8WO"T3?@_: N5MC$'I'2; ,;M;05;F,0_QJP>9?6P+Q+=2!M5WF/7&].[1 M9A+H0,B5!Z22@M MV )[JOF#)CG,C6.NHR 06,KD/Q/;H,P:"[P%AD"LP0=I#O-DB.'P,!N&K;1A M6&Z#PSP98GAZF VGK;3AM-P&A]ERCN%8?[P1]_P9>*(/@-MCP1YGT #GJ7+" M+XKH1MP*_D3BG495+NR5:(\5-N*@'\[3Z;2_Q-.(.F=#C&R/_EG"H.[.T^F$ MW"V7"M&_R;IJYFK#M\>#(FW0"8?9==(SS&T7:&E7#M)HO8M,08D=IM#F.C02 M&,'=.XMHML#[1$%]'>;#G[AY.K3DK/3^\SZJT3I;R8):NTQKS:X_"0X5NZ\; MK6Z>)23KZ^R7J"?KGX(HS(IHA39:;I@Q*+W#U'3**?&U2FSQ M6<= ;AZGI%/NA'CBW@^'LWNR1!T:E/52CM;>2 M!;5VF(Y^X?<"F9?]3+>K&:?P=B(+L-&*0WQ!T1UFGCEF=KESD$8+760*2NPP M\TQ/N*N-OT1L@>'5(C9DHP4'"8.Z.\Q(7P:Z1:VQ>]&FL7M18^QVF)&FQ.+- M OH0F=?*B57$[%I_L-M@A3;: )@Q M*+W+K;IA0!0.8I+7A"'FZZ1O%QAP-Z&J5+,-J4,>],;Y<]<_,:6_,?[,IAA) MSG 0)Q]E3SR (HUVI9HY:(GS)[%?.0V9>7U$]$I.X!RQ0EM@@8TQ*+WSAZ[) MLO;=U2Q^_VB9 _82+3"BA#CHA_.'L1.FL$"^(D_X$BF4<"[SPUZB!7Z4$ ?] M<+[@.3IIQSJF!2]?DY #MD#](E]0=.?KG*I$ =T& M&^RD(0_.CK"M=^3[9BE+/%=@ 1* "S"^T3Y4T :=<)A.WYAW%V=G;!$]$U#9 M(I.J4HUVI19YT!OGZ73VU12EE^H,KM'Z W1!Q9UGR[?AC!+_FG)4FA=D8"W0 M>Y\M*+?S#/DC8H\B7"M_>RNXC[%YP"1WYV>-!*U6!2VPJ'XY"@IUP*K*NF##AWAE5KR92LA#CYN[_ <"[,PY!YOU$?= MV&/YI*NR>*/].BP*T+9,BOZAMQ>@;OY1?Y<<-S_,W[S11_X/4$L#!!0 ( M '(X!%6.SM@&ULS9U= M<]NX%8;O.]/_@&IOVIG(LNQMI_8FN^/X8\>SCNU&3K9MII.!2$CFF *\(&5+ M_[[X("D2Q"%I;Q9 +A*%? _X@G@$@!1Q^/:GS2I%3X1G":/O1M.]_1$B-&)Q M0I?O1I]FXY/9Z>7E"&4YIC%.&27O1I2-?OKQSW]"XL_;OXS'Z"(A:7R,SE@T MOJ0+]@.ZQBMRC'XFE'"<,_X#^HS3M=S"+I*4<'3*5H\IR8G8H0]\C/Z^-SV< MH_%X0+F?"8T9__3QLBKW/L\?L^/)Y/GY>8^R)_S,^$.V%['5L )G.<[7657: M_F:_^*/#WZ8)?3B6?\UQ1I X7S0[WF3)NY$\;G'8Y\,]QI>3@_W]Z>3?'ZYF MT3U9X7%"Y7F+R*B,DJ78XJ9'1T<3M;>4MI2;.4_+8QQ.2CM5R6)OTJ&O.!4I9($D;%MGM.%G8S*><3&3^A9(ES$LL#'FUG]=4;KP2GQH6R287 QB)2Y.R MB(X>6!U!#0Q%V57I+&J4F\K>G/%VW>7(J,IDY(H9A$3 QGC_DXU:=>AR\X6PVR49PY-D#\-9U7Y>M3+2P %6G( M.,G8FD?D12U=K\W0LUHX7*4B0D[;"!U_FHU^5#+$%D@)T1"*467L UG-"0?J;-&Y) BT62>G)0J&&,A9BQ2E*SG1TM]-RCS:1K+Y#_;_ MN?^]:GRYY>O)2@S\$:9GY)%EB1C^M[-[+"INQ6!0A L@7F!=HC% [AV2X1Y- M7,H@M(M".NR;P?.M!ZX[/-_-"Z!^M1!Y&:(:!JWCDE)XIZ;3E@E*)4)?E"PX M+,3LC%R*C[T3F9K0"QXMHU9$*E5XF)C6.E"14J2TWY:7C$1[2_8TB4FB4/GM M>_EQK#\J/L1_OYZQ:*VX%J4:E6KO=L$"9$H28.[SWNZ (;.U2PF2&@^-+$8P M&DL#%RE>6JI@['?5S%9;93LW=@;1T#9'EKF"UB I\MG49R2+>/(H[WAVU:4A M<][P%I.M]J]IPL*@;0RFH:;UV,E_),LDR[FZ#5Z-0!U=&J!W/0QTVC;'!:LX M"'"&. 1'CGH0JJ(\LG1"Z1JG'\4E$>]"J"ES38[-I E,71,4)Q9C(!Y:B[38 M(Q7_6F.>$YYN>\%H*5VS 5@U\3!D01%B]P9"4LG])T MVUT,5>)@,3(=#B1)A2$9YY&FVE,P-YT7*D]&& 1;)+G'%!V2NY,+<'P0/@"F3 RU#4H>TT%OKE[\J MT%RN#0&K9,K<4F WV22AJ0F(!JLQ@(B=5BW5\4;%J>BE.$XO:4PVOY M6+>6 MSBT7@,TF&(8H(#+LS@ T"C%2:B3DWN"XY91#W#1EOH%@_(:),/4Q40 M(( U@)!"C6:7I[Y'E3N\N8P%L,DBT4ON>D@!]6Z!Z;'=Y 80!X1/MT. (A&$ MFE&^8;JD$>./K/:XQ"E;B\YP>\IB>,;2$^46K$%5:.+5&1(09$-\ J@U0M_H M9UH0D\NE50%(EN"-NI,X%BX A@KE MF_(#DC'HAH8$SL$+JGO@'YR#H> TIH!$^C(;D7: #35G(,;7CXV WV,51-DLLXWR 5D_7>+TLI\]/; M-$W:NQJM"0^4IK'>3D:K?6-QR[(U M1WZS6%A'_RZQ*S#Z#9> P,H@0.FU9P(C L91+0+I$*1B_*-SF65KPE\$D"7$ M$T:@>0"FECY$I""3O6#I0-]\S4BT%N/E=GHPOTOR5FH\N\39^ 28JT8G8W\0 M? "F3![4/IF4=7KPU_G?4!GE 8%K=L>QS/,_VZ[F+ 4R85E5KD#HL%BR8)$$ M@0/LRR3BFJ%"BK365Z:LAF%+E8S]KB"PVBJ;O[$SB(:W.6IU HWV]MC]GV^B M>V&, (L=[#+7PX#-I#D4U#5!8-!AK'6Q4DA1J?6UV&$WA"W[)P5+;Y."9<^D M8!GBI& Y=%*P]#HI* ^MTY2(/NIFGB9+#"1-[%2[!J/#LLF(11H4+K _L.^H M0M NQD>V395V3;Y=B:^4APOQP5)30.&I* >+#Y GA04E1JO?%POB)\*8:[GSE[SN^+'+)@_0"U6SXZ M+3H8'="LP4U+%Q(TD+D6 M,2F)Y/V8:Y:C.X8^903E]P2=%V\:KF>NU^7X?$M*%,D%%WJV3F/,;1AUB9V_ M,04TW'IO2DL9!$R]]N!WJ%01J SQ0,Z-8)G7K_&4$?E^0' E17^(*XJ&FB]9 MZM,'0=1 DR97*JQYX:T"U;L>?6=5JB?DAZ=]#9'CV;+%H#%9KBF"X 2T!4V5 MZ^\W\)?/;SU/D^@B91B^"]/0.,[BU[9G)/#;"0*BH.T*2MNGA$@IO3'P'M,' MOG[,H^TM9Q$A\FFMK.JY^N[1#8QVR\V+JM0D:E!H0*R]Q"] X:X(5"OC36WT M\GW#3SZ,+C/,L>A!OWO]9IUG)CHB \!M@$_IQ M0D4B%?H&Z6!4B_9XW9;MLA.2^/WV(UD0+M@.# /&E;J%+P S5"T!S^9Q9403Z(@M!JI3.][3_ 2TYC[:1?.TP3R), MST27G"7R%V']A?E S NK ?*O,8NK:R"T"ZJZ$(LK5/? M="4^B&ULU5U-<]LV%+QWIO^!5J1*,RG.6KVC;BNB(I8)$].SUL=1^WPT& Y;D39$)(1+0<]:0K9>__;C M#Y']]^JG=CNZ8I0GI]&%C-M#,9$OHP\DI:?16RJH(D:JE]$GPC-W1EXQ3E4T MD.F<4T/M!^N*3Z.?CWK'XZC=!ESW$Q6)5!_OAMOKSHR9Z]-.9[%8' GY2!92 M/>BC6*:P"XX,,9G>7JV[[!;_UL5?<28>3MV/,=$TLGH)?;K4[*SEZBVJ71P? M237M]+O=7N>/]]>C>$93TF;"Z1;3UJ:4NTI5N=[)R4DG_W0#+2&78\4W=1QW M-N%LKVP_90'\3B2:G>H\O&L9$Y/;7EM-Y$6XW]H;6-N=:O?Z[>/>T5(GK8WX MN8)*[A&%C%MHN(RW@N$.U_D >M-&\_5US0^ MFLK'3D*9=:'?^_NY.VRO#W-)[*]?\LK.Q]HH$IO-U3@94Y[7\<5B#B"=?QW9 MA.AQWC@RW9X2,L_#ZU!N].9,'F6[VRO:R+/B]!=W%U(GTST9.^=*X1; 0]QA MS+L>GZO]^(F*-Q>VAWL&EUMV@>C,B;+7:\XO@6K,;V(5,"1-^3ZJP#3/#U\ .?*EB4AB"[8=,4RGRP-[3=/SU MB[?"CC*TSHUMA_"=?/"WID,#?#1W6LHWV5 >/KDS7\Y3JEA,Q 6=2\T,4:O1 MS!+27HU=J;I"0+6/\=2&L/AO=/^& =QFX'AOKUH]?MM' .7^7FK[QQ(;M4L1 MHTEK/1>)B^.*DVFUM@<0H+@]5'4K:6'*>T%UK-C%L>82[#T\1[.[[21U*D#:B'>="9(3?V>\65>/"/A(H_O-&B%]% M$E'SWS.B#%5\!9&]! 8J_W,CE/=0Q1RM*"+L,,J*!5&_C ;*_TLCY/>11=1_ M-*.Z,&OC?# 3[@A+EP^ND&"900W8J<(T(L7C?.B1!O1CEN; MXLG$4E$ (TI@H 4GC;# 0Q5=_$N10*7?0L%)5X.4/^")J/L5TS'AZZBN[+FJ MI\D[X5? H?KC9KVU?-$]^),2!79@!PS5'S<1KN&*H/X@4VHOH&#GXT=#]<=- M@>O8(AAP*0PS*S?=XT/F>8!L86445'#:'X,12S57.X\]1[(S-ZMJX%, M@E\#-06AWN!FO$_0 ,VA\R2QVNGB/\>F%_*E$@Y^&]8 -P)\&^1!_VD>].$> MX&;"M7P;Y,'QTSPXAGN FPW7\L7V8& /;]2]7'A>R7O!4/UQL^$:KMCJYQQN MU*V2CVP](;_.@E()J ]-2)+#K+'-*$8*D/M@@X2*WX2$N9HEMNBW4AO"_V+S MND%J-1YJ0!-2YQ!CC,>BZX;@GJ/XYF,=0*!BXV;+E;PP]'66*TK\#7L? 547 M-P6N8H4@[K5T+W=F4@0?*9=14)%Q8N=C\ 1!W*[XD ^" MII\5,S8*-ZL_$\4S),_+0 \4JC5N AKDB:#[2'(6,\/$]+V-7C'"JT6OPD$5 MQTTW_0P1Y+Y5U%E/[1 _GQWG%M2JF\G$UUN'\%#Y<;/->L;X-@RUSJAZJAD5 MI:"6X":>4/88W1&-,]M#KGK]\;U;)^[IC$HHJ/"X2:>/'8+0'^2](FX3B]$J M'4ON7^53"83*C9MB!C@B*+X72[76!Q"HRKBY924OQ*[C@OKKZ1/[:]RCU_'U[O]V,.9L2_[K!8 'PVJE&R!_@ MC+%T,U_*Y?9'4FD>RY4]J/; X6JC[Q4-L030_S1WEU\IIR_$W(A1I1H*6BR3BM"KR^\1:"6-.$]:@UO-#\^ M29X)MU=#OJ6O.\D/R^$E 7FO B-F"]XC%H0P4:O,U%$SSPLL7D*,0FA]27PIJ"6["#&6/]^6\LQ-$\+MY#P<5 MOPFI<15#O$5QV9BS^(I+$AS_[\&@8C5#8W\>I6R9A2]WY( M;^]%0!8&O #4GR9DR$_2!._IQ===5==[?-YD)O_3!C;&X#.,8#FH3TU(GB$* M((ZI]-?5?#1YL[JC$ZK<1(Y[NC1O;&4/X2$6H#C4K&;L;076H\*S5YT205OE M@_VT^,3]<'^VP9[Y!U!+ P04 " !R. 15G$8+P$ 6 ##>P $@ '1M M,C(R,C0X-V0Q7SAK+FAT;>T]:5/B2M??K?(_],.MN>4\(TM8%-#A*01U&!U M8$9GZE99G:2!:$@P"\O\^O><[@0")(J*.G/?\5Y'DE[.TJ?/U@N'_YL,=#)B MEJV9QL>8E$C%"#,44]6,WL>8ZW3C^=C_2MM;AWT'ZD%=P_X8ZSO.L)A,CL?C MQ#B3,*U>4BH4"LD)UHF)2L5):+UT*B4EK[Z2XK"A:I.:-6M\WEU)[S^O&K2L:AA=TUK0!T80^PI%T^EX^F]0"=Q MFRD+'<%SHF>.'NPG'\](?C\K@[-(*1;+U)YQ7&5+[/9A0@&T2$MW6;^JQ;J1 M'>\EH=2OZ-KQ'J7#6>4NM65>T2O@_<934@!K*+%,G=FA;7A)2"/5L>+.=,CL M<+2@.(G%V#*%+=.SEHKI&HXU#:?<*^0 _0:VY:RB!B]#L)*5Z7P490V>=.;T MF46'S'4TQ4XHY@";I5/Y5#;&9RVC*OPE^'/H:([.2H=)\1=*!\RA!+N+LSM7 M&WV,54S#8883[P!M,:*(IX\QATVOO[;?I:NGY7(3_B!5)!Y?MW7FY!JIOHZ@]MJG]A%= M9O=FK9[2/"==,Y!@( 7^/S: F=,*<,FB>LU0V>2,3:]3H.7V]Z0]*?V8?@N! M?LL#9JCPZYSHM'?=I;K-'M'5?OJZW;CNB*[^J;*A*$V*>+48A;.6?ZDJ2HS^ S&1ZA8AW&P-$5,SHG30LUY M8ID#E&14UZFL8\X_QX@!5 ,HIA5#9356F@OK87(!Q'.@"BGY& /34Y1-4++4 MX$(=.BD!NQUM*ZF<)D&&#*SD"?Q ME/AY%D+S3]>>?;JNF(.!:;0=4[G]PCBP,%XYELM6*$CG@Q34S8Y%T4MK3P>R MJ0L>8KM0C),+LH0$@%%E%GAZS!8UT'H7;>Z6 26$^UK%/C?,J(#COJ9,3&PU MYA6C"?P8LS50($R8!@_48N<"G&VZE@\-JO&)5?1XQTF]9S!]$^8W8WSX9F]G M[S5O-)E%."DLU.>IU,X6Q7ZY\1Q<,A2>!VT(_#7552S \;2<*JC4TIP$OZ=Y MV4HSF T1C?R29;06$/!?>BQ=E\]KR>A;\7_.4M9#31$H\(I40&8RU#5%]B^HE/;;G0Y:>6)9L=*?I45F@^3H=T'44N&X_;_2V@4 MUW; #RMS94,-<#9,6P-\I\*F_NL%")5C\7[J_XA2T34T(4?@4ZT(PX!1V[58 MR7.^BE#'[\PO6@2!O47T+_@>"<)C J_T9!ASCW$%#GAW((6KO,6VW"!3Q[16 MA? 1/%C&,:S7 - J,\R!9CP$]F&^+,,-Z]@O7^#""D,]#R'@#PCWQ'=\#Y/0 M'O[B?X=#WUD>4*NG&44"7G8,8M@AKQ#T\5NNSN)-VN.!4M#-%BWCCCD$)ST] MA$C >R.;#JBN(LG@N[&F.GWTXE/O8@O-9=,"O$3S(YTJMP3Z(+:I:^H!\0K] MGD2Y-"_'T"!N:S\A\) 0\;__DO92!X)"[]\ "O%% DJ(UG_'N9[GTJ(X!(FZ%!+GVMUSK'5=+NE#O'[4/9XBYH^[CR MM57KU([;I%RODN.KRJ=R_?285!I?OM3:[5JC[M>\I'8?'&C'!/#51"5!TJE< MMG"8E-^8/]E-\>>DT?I"#NTA-?Q8XKJ0VN=IAGC<#^DQUW.MS#(B\]S(ST&[ MK0Y:^\[G#GC@SPX_@_!BI7S\;#E0.4PBIJ6WY_^&YACG>Z!G7P]DN0:32R"F MK>-ZA[2.FXU6QQ=*0;[@A!S=208[:;J6[4*T2!P3$%,P@H428EI$RNVH[XG9 M)4Z?89%K:8X&!!U/E#XU0+^4%0>+I4(F^WI\!X)\UM\#*_VR[$]Y[']H7C2Y MK?GT"1*,_E7T,J%=7Z73*0-;;(1-H 7$8J6RVP,7 MG&1W"79[[Z3R/K[H&"-2*%DM<(4MA^SXST".#A+H$#:"FL3BQ4Q]OS%T7D^M M+DO.L2.C8!104"8KV@@#A4!OXH M3->! PI?\$S%^/.0JJK__&B@ 4]RYB JIJ[3H0WZQ_\D0H=#Q_(!C)@%0T1U MGVO@(18)K=7(>SNB+7G]P5O_V+7>1CA&^UOHQ5BQ>5:^* MQ?FZPA):*.1Q;1(7.7J^.!58N"C53="10TP>H/>JE#%+P@'Y#*);*H[I FQS)A. MR9&KZH7>0AB]%?C8L#KFV BG]NOEYYN!/OPYOLQM MFMHYZ%BI0@>RI:F]E>7T1:(B1O(HE#+AC8:3]?/G='):'G4,#.DWY#1[OC)2 M&^8O+Z(5*WTU- C(Q?">P8BJYN >XL.R\R))GEI)L*=$QCGDKAPU9T[0=JO_0AM'1SK?V3:79NJR-Y,V%\F'0022/TI+@WMYI^UXG M^TE>H%]KT[S>\:C!D']H@3>F#:E.V(0IKJ.-,!, UIG9[\.E8^/8 #L)\O/] M6[H ST]ES+,]?_^53TO[!S9 U=FP;QJ,&-S=VT775W>1482"H@9Q5($W(;*? M\V0?%6 9:D9+N[8_.G-O4OU\+K\!:0_"BY4^9+,14KVB7R4/X7,3Q+F)--\7 M^:8^3T8WS#G14_H&D%Z&&2M)Z71F>RN])^52F=?(KOGB]*++&#>N#7XSF(5* MGRFW?!T!(E#+A"F,X9QL3HC,='-,-+'(< +&A^3C9Z2KZ2AQF@WBYS"8!&!2 M')/8VL#5'6HPT[7U*;'!'[>[4][4:V'* %FXZ=["12!#Z$)'%J'&U"_K@D-K MCK$=IH4TC*7LXFOD"H-.^K(3_SRG?<&(AJQ3BWS%@_I\-5?"[2]JN]621#J' M^FDU1]*E TV?%LDE>@+P:Y/T6M56W7K?&;JT- <$ F-?U_ ",CM\QEJ9VW9E MP/9&5T]7,^ML00U%28Q]_B!R*B_^$7PM>5T!>L&^R#"P1(>K^R2;SGG"O+0T MARMR.](^J9RT2#J32D#%@(V:VZ?G2/<#LO5'YCS+=-ON$+*GT!K0FJ M4X\0^(;)*DZ])>?V7E3@5_%YFK3/^X$!$QVMBKJ4I7$I'9#VA=7GF:QG4PE1 M\X^X_Z[B[F3Q-_ MZ"^N!#I\4.M+636>WI'?KS<91-T_T^%WG0[Y\.E0LVV760].BN;WB[.:Y5)] M3WG-2;&"W6M-C0R+9W>4]::&5_>-I\8+15H!9U!$/LQBZ@+#9IN\4#]L;WFA M$'!IU&SFP4SC3"@T(R()M9IS6DH'I;CRD4L= M7!@6&Z.4/E'P7,$L>1>!>G /<@!]K]##.*HX>^:H.9O6XK\&;^=3?0#+WF?SQR@6=*Z7K<4SD8A]D&1:$ M,BPB]>H-27B2,8N$8JI+<](XHTZ!T.^4.N6.>3\O/+?/TH^8B_^YI2\.*8:C]]_4A."KT&]?HZMUN79EVZA,WZBP_!H^5D@,%8ZJGRO_.L&-\3:+*N(S5B;=8PZ MH-;T*1X% 68:(NNQO376G#[/>.@0(7'=YR5 (A4FAE4@/$2P@BS3G-ATVF2% MR-?('$7!KADJIMT8D:=$X:OXT-,I">;%G9,^ MQ%,.L"+@11SIO1QU\[?.%ZW[]+VBZ^26[T%LW;3ROWEB=N^9:;AM:VG>;F_Q MB:NM[(KIPZQD.JA'F)6&R5/$KLUX+0#,-]\0?JVCQM/&XKX.KFL1F#Y%Z%RI MX@PW@% HL=A(LZ$=S'5J*+BP2Q6^DQ0J;V_AI9HJM51;;+M1HQ+4F1TZ.W\< MG,,)LI; ^R+R.\O"JL%[ZJT5F9!U"7&3Q2-NK7C(IPO<:O&KW%H1S<'7'"*D M[ !ZN7-Q30N "3*Y&[W*\4A'^<%K2/8X N$7GLPEU+\=906\Q>AM7&8PN0'' M(<"S(X\*\RYJ%['7^1Q6F82C#*H+]=0\6%*M,J8A;? =Y[3W]E M^,_S3OM*X0O62\<8\3).P:9T(I5.1)ZW?+BG%K-=W>$[MAM#9GDKMWAP]F1F M%"HF6"EQAB_J_.'F0HC76H%M&&3Q.H5=$G6,GNR@:!).GB_ MO:7A8KI**!GRK>\6&&D*AID:!H@*RF? O%H>MWD(Q+?#VB 8Y,[EY]^)L.*? M78.13$I@Q8="G*:471M\<@#1!Y]41[_43I R2-\0=\H*'W\1!_"29<8Q<"U# ML_N()OK9?4W6','F0B$AH37G+G7%M2Q6GK*Y2O(6LOE7,3> MS&Z=V?Q>F\S7B?;61J>LVR9JDF5C WS;WO*,"0%5@%,*3+4[5/GLFDTTXN7_ MO=,2!I\J 2/$SP.-F0QQ'TN0CHDA'-H WQKX33'6'#';,2T;IK;IZBK!HQ2. M0,33(LT@++0\8F!]Q>7I!U]!16!!0)/,8"4B;G/?9#KN=Q6-9>LTL]+;6[X" M!:,TFWJO9U]XZ@UU]/964$FO;T$29)FV,-R7S D)6A. P4\ #/1=6G87[C@J@WH"K/KP1$=A^P(H+J,0-$5%^\1(+HT*6+L8]O M6C9M6)XK1'_,4B'$+,V#E]D*D"\EW&W[M]JJM2'OJ.^CTM2K_\Z9]N8Z^_?= MC3J;'G+4MLS\N_M#_Y"Y(Y>\L<'K3M:]=DEZX-JE-?'-2^\>?PM3* U59BN6 M-KP_Q;#V%4>'E(@O,W &:?C)YO=5Z9I-"H6XE.@[@YET\!U<@+Y%%9 2)OCX M4/(%([T9?G2M*W9>%)\F#_A;LX"?YR(6?4W/UH5G(E GAB06EDE\RC#4 MRH9GK%[REJ)8B7\1#D_SDAH**[ :+R:H4H<2?GW2#B[&JYB&06=#$^YVC7]S M%L$OU-G>4KV[.=\'LZ8OMI[^5J;D3W[\#?/CZYWZETV(X39T=U:[=EHO=[ZV MCMNO >T-%F13B2SZC,%KE,4"ZYVK6<(_G!VR>3 P"EF:55U]2A3JXG(J#]O$ MK;<(!P(>&S"# E-<=RHS"(:Z?DC"0SVO @0[S(78![0,]D==IV]:H#75%X\W MPICUZZ9[ [BM%_ (C?1:QQ@1K8?-Y,-&$B]4+I+E6Y\7K2;Z;6 +\.7'6.@I MQJ#SQ5^,J*51I-X>0% >5\"UY6Y8]#7"H3[9NC0N6?1EA /%7L<+7:^0L Q+ M<#[$[5YI.;]FZG[_]]&BD8,.CZ;%M;SIT.^->!2T+()+VDERSA@YH[HYMF^U M2"]M8_S;#,]B_$Q4!*O6[^3W))UO^GXV[96^QKJ!Y=D&OU7+>K45V8@O:UG/ M8TP?D 8/].PB.:>@UGX9!_)A;RY ZGT<^5TWPO OI#!5_.ZI0_X5L*4UOUDS M?W3-MZ#QBYD"W\C)/D\*-\[)V?AG^6M_^*&WGZG6"NI-NWIRLO]MSV[8K<;P M8MR9U*P?QNE@,IW>WJ8S[69.O_L^_)YAIQ?EFV0AEQQ5JL>=LWU3:G;.\E?5 MKY)<+S=&%]E:]7*OE9*_?M>8Y8[,:K8^ZO>[IU7G8F0R;7)U4K7E1KHSN6KT MOG_.M-SFU<5)^USMG%QH@XM<_FIZ;-])TR\T7[,4Z9,\[*GE)%6[U5K]O'ID M-F_''?7&_)3Y?%M-&=)-8UQW+\ZG[H^?VI54GGY+'I594JHG&Y=]2W-;/]7S MSY/:<%C/3JEQ4;C-TA^?3B7IP]TPYU[>?:MW3D[HCWK]3LVFJJS3=//=]O"T MFZ+['6>:.VM];><&5V8R61OW!J=:-YOIU]5ANNZTDF/U\\FGQD"P]?\ 4$L# M!!0 ( '(X!%46P-ZYA!L ,S@ 6 =&TR,C(R-#@W9#%?97@Y.2TQ M+FAT;>T]:5/CN+;?4Y7_H$OU[8(J)V1?&H:ZD- SW(&& 7JFYM,KQ58233NV MVPN0^^O?.9*\)$Y"R +IQE,U#7B1CLZ^R3K^[?[J\B2?._[M_+0+/PG^=WQ_ M<7]Y?G)\*'_"W4-U^_CLNOLWN;O_^_+\E[V^;?F?2+GD^.2>CYA'OK!'\=F37Z F'\!C M+A\,_2.2>.OX[.3\:W'8!Y5('_:JVF4?X_]M1N%\I\1 >E@T \Z_'_,0DPC'2(0\U8^(JK>@Y-/=LTEAHU23N3]2/2%7S; M$7-%%WJV[]LC<4T0]8SK8]UDY'[(7.JPP.>Z1VZ98[N^!Z/KMF60/P+J^LPE ME5*EDL]]YA:U=$Y->,P+3'B,PC,WKOW #8"Q8[OP,O49^>H8\&,VIR0!UID% MHTMTOP2)SR\NQ.X;05"0\Z?_/;XXZ$A Q]2NS$ )]F,^Q)V !CS\PP"-*UX#K1+=-D_90V.!YC?B@M0< M!K ')1_*)0)*SL21'#H>(7_X]EMR1:AI@$O_J+X9(.O;I949KT 6Z0/J#84B MU?$7]CW@#]2$T5&*\KD/U6:EV(H(2H5L_3>P&*F6-*&7-2(X!#7PAW;BT:^_ MD]N/=.0<=9 8;<93H#CC*0)/\-S+&8/^*YD&V.4*DPW8?G M^J'JS^?W M%]U?S[5\[MP:F(!IC0BZD+/KN_OK+QHY#08P-:E)>A)IM82_\=$R@"G@R5FV M.@UFV M6*A'+%@ELH7!^WWF CMPZ@NC13U/6:$8EAXH>X, UW'@6S!GCLN93]TQ3(20 M@\IRF..#FT#V8X7PT64#0>8#8,X(&E!GM@$,Y@I7),E[<$FZ'7W;%4;0DU[* M=^6E,,N QR>$0ZS D1Z*(=@>M*$>.2J!<%2\XI;Y;'-.\2KL_-$TO@?VT5^, M4)<1QV2"5H_<'PHDALY'/@=$M0.7/ [!NH"]?K22/HIMZ9)90N<$>2"AW)&. M]_83*!1PQ(DU/1D?0;I][U@Y'M%H!G!@R(GL_Q MT0@)J3/3)'1@6]SS!;^(0:?GO>BH MDBGS!"W(H1K"I,7U@SNT\@C6CBNQ 0?B%PR MDO"+$,/S?2--BAQ[8*;M"-,M;K5*I;:XO?T## ME!Y+X-AX +$15A?NE![4YKC6B*G@.U/2*"E7O00R >-0 &XB.4SX'-'L$ MY088-S'P1<+9@&C+#A!U"2JSI'>&-!3\:1M=%'@=@ M5(Q1)+.E'U8YI, (%)U*&P#I45-PBS=DS >\##F /62FXQ$O<% 3"\@44X6< MB8!-"+5\#[!* 0"=.ZADG3! I$E5/N5%[ @++AUWK^%=G)W,B*X%]FZ%??\\O+FM-N]^/+K+WNE/?'WWWX<@/S/510X7H@Q.2&/_Q$*M5B6^:& M#N^[)^G[Y5:Q)._/]>KNQB.@^PSW[>.(&X;M'T79G\D9YI'W5.D/@WP64?J- MBM*[MB==;I2D.-SKS R:[U$SBQ! 6H:B\ LO+.G?2,<_M%,TFM ?4G]&?N 1 MS(.1G'VF:<(;"TP30!+Z;1Z*JJ=T8V$ >D[IO6GE-.D0D/W8&S@@TM:C%CQW MAJ>5(OGJH%ZJ-T*P/5"C8/U[ *[E@GJ-P ?O0!A:,[T.+79L:(^;W!_CF/W M17=5/FZHX802BQQ7?"/R+UU[I,RI&K9(XB 6M+7AX:A*L>5SZ#^;Z+9$(RAL M(LX)\X"/)7I0CRH;@KT"?Z0N[%C"X\CP8N2 0_O;_$?%-HM)2.7 M4PA3<@9Z8?/)@X4*88Z"74-+I/.I;Z,W9N>"R(7T.:Y#GZ.3]#F*6#E0&@+< M]X4:(AZ2/3%7YR@#%"9S!'<":X>.K(H#E8W7E "%7/IL:@I"38@MI+L@Y#*$ M!Z8PN*?;#^@X*W=7)D'LT0@A O3\CQ$+'C"GE(J( @I2;J>=,!F3T&-V0#AQU4;2KU-+CM'0&R>P$T!$*4--$,-1)-:VRX%506(_LYX;8)@+ MV"Z1>*VX$I640\PF @50 M/*104 6YX^[%GY-E+:FDRI496JJ!UX#;@4VB:V:J?/C/K2HY%9"^E;YG/"N>R$KH_T M)[PB*?\->$:X\HT-)-HJC3P-#%WYHTAU >(] 69JMC_S>>^ M8%[&*M2$X1#9KO_A])UNN=I<0KO/Y*AWY@QN0L@6O?2F<>0%%IOX*,P$*I:< M%J*H*C]#F/*Y4\\#>9)Q"";0.YC(8+IR:GC-*!9!PH)N+$4$R*Y%3X8E<"\&98!ZLVX\A1 M9+=ZC%F3<>\".&!0X"-?7BI71+K4MC!^>Z!F0'NPX,"U81 37],E]O:_=@X6 M3CJR+5MZI>-DJ%TIUD>#P]'QW=>;D\KQ(?X 7QF$OUXL3=\@CXQ],\?A$FQK M8 O=A. 7R6?,P\5%6VD=#MWP"#"=_XT8ZA2\W@ M^;B"? XB!,Q6DOV[[D&1G*-2?ME*YR-3I0GZ(H$Y%Y#$8N(@/[$NG?0!Q0?M1, M8%54LG"$9OW?),099H!=VQ0WYX@+,A.LC(.E-0(E=O!4-.Z0&F#5?#)FOF1J M\$;UH61KQI&I0890SQ3K)(5F0,LL[$L12&(_ZF=Y"#$+OK2GF#U.P !38"Y( M)FJ$--$^FFN@,J:T_7RN4A.T]9[-DFS56FYEELB%WL,N$=..B166,C![!%PO MD_!]5\8U$ ='E0!/D_IE?AHK2I*IHBC&FAX0G[HSRJ-OCL,7)NJ3B&RHRGRJ MG>WY=K'UE_HS9>!_>!]K?NN-L"/+]-Z(U@E7VHP/M6JKV)QZOLMT-NJAKJR6 MQ4MES$UAQ5%WA:8&32>FY]@XP8$HL$Y0R")')FX$RI6P'>$Q[9NP;>2R3_<*8/+00BL@V;?<+K8C;@Q[9J03(FK1WJR.F9BEP;H#3Y?+ M"99>AXC7W17(*5*=49 M(8.)&0%WF+Z>B2L-Y?11=)EXB8E!UCS;LIA9<)DI.CJB%S!M$#I['\K%1K06 M6)L8 ,<'JV+95D$(L#<$=*J,-2(7AJ$JZQS!8!F)R?M4Q](5R'=J]@W6@&:R M=";P.RCPOXJXV)39(6/$L1D*3<$#2XE\.6&P5A7Y9K&ZKL2CF-Q(PG:ES"T%W69^Y2LF!>E6 >%)+J2RI)[MAL#%6='JH M]&]O#-897"Q1FDMN7%7&V'>=F2;3 \ M)YY.^WW@0Y&$$^V^F (V;=M1<&$>G&,?C(""N]AE$^A^@*[@@-DCYKMCU>@2 MS>6'P8-,X8G2">EQV;,CH, ")X&9L<5';OSQF$@Q/\#?&E#QFRC91@OUL<$< M?'YD<%%AT@T$RIDHTR7DJ/^_+\J]J;5_8,#AK!\&PYFX]<" 81%GABAK8S>7 M*A3%,]'I"G8,3D\T3Z6*@E]_)QV@+#([X*B+!._.(?B044,U)HE\53[7H:.> MRXT!N 9??UH.9"X"WO/5]J?_C+3\8)=W-NBCU"M MCN@.@;A1!),C.A8U%5"U*!*(NH(I49?/>1'NX#D#HM3 ]0(J6_UD(-O'LIH+ MGIVLNGA" ,+6:Y<_H,Z[ _/@BNP/N>1"IE&=W3)A(DYE%%ENM^LBY/9$N32> M=0RF$R0 NZEXGTO!?@1'$K=Q8,;0"S>$4)[8(A5>BS9MI&[UF,E!\%/7=3LP MC?!BO$4*E=%HUCBROS%U&5U1B*[3-P8V-:>OJ=I5>E98_O2SCDFMU* .!"X< MPO+T=;439_J&AX7%Z8O8G!Y> AT&FH:ZLK\B)"D01^(>Z.UQ"*RH:$%'AA)/ M1=Z'7)%T5A3MQM/LE: S6 73']H!&'(LT()7D<_-?SKBUP1$0EO.>UX\FN)\ MF21VA%W)+<%) =7WTL0MM"(=CFJU,XT5%,;XH[D!H('"B13NPC@)0"'RI:6 M68]/N(KQIBYA.&,OPA-N!%9SPD8VA$ZTB!#J.":,*CCH* 6BX&1D$+6) ;$5 M]E"/,<&$97)9Y 7;;8XGLMWAIDWEWDP-G=[FK?9GQ08>]9[@-? _*;J]8'A1 M(83[U2R9%Q>+%@+@JE&50""D9J(3QV.+^1N@'-L!NM2@7\3,,(DN_/0 &P5, M+K:KV6JP1?Q?1*49)+8/(VP/2C)P=+G#F:"^0G+"XJ*^);DRDE@8E9L!9ZQ, M^%W/+0TU,%60($^ASK ##[UVWW:3S([?XO&^"8I/>VT@ /^[$0.!-%CKCO/!;*GJHWX,T1@Y!!<612GL G0Q92#AL'7@8O#.4S M[JSLC65+2.AZ=J[_O.@6RFV"',M&7#\BV##FHCH2TW%K*/:6AWG=>%7A;@#L MN5%".R5U\HGP6H+;Q3[*E/BD%(L4A<$ME?U?@P[*9F $P&SV+V[$09>&>* <_ MY2"W\Z9P@]L=Q'SQT.&.*=N-NO4F8$K%!K/GD;TZ5E*:Y$753>=*59BXV0\@ M8F43BC7&N:(DHKPG=N'2L=B*8D14D!UAP!*>%)%QA*"CA)(%2X+AN\JSHQJ$ M.1#UD23[3 3T"&$@"Q0KDV^ (495"Q=A M%#,#L/BS$=>S3BTDO8OSOO'*"!N0*BUB7 EY &,DK7(Q9O&<'%4"!$=&/2QPU\ MOT,FE1O%:EWM6%FB@K#NZ,M4$*I9!6$+&Y->1N>5ZA.-6K$93E$K-E*;=N0' MI.9_B<\Q]4UN_G\!.!ULP;705>]@=C!,D\:)(>%?73LJT2HU*"A.4#!#> \= MA4L(L-\(^GWQ=19PJ2FF"$+M(2J4,A ,ZY4BG#O82))K55"_6A1\.D#N0C#6 M5C-KM)R&\BX5B=C;ZW@@\N%O<>W\13M^]H2 +ZCV2Z6Q%^J!N)"^1OHQQ'R( MC/ONZPW?N4:T?OEEK[FWP:GN1:']2A;:SS$^6=1W,/E=O24G?FX]C;T-3G7' MGUYQ-:+_8%4^G ?*9%-(8K(-K@("'ZP368/8MD[-MEU"/>]8A TGRRQ]QEK6 MHFJ&Z%="]+L2G\IK4A5#S?5_8 M>%$8LRB66&' 6=!_F ?HRSZQD#KD8>^DIE6;K0V@81;4LX7Q_>&XK#5;];?$ M\3R/ZCE4)MY;"6-SWU>(::'D+P_[3[?^JE9O5S>W_K5T\5]#[K.YR9;5F/,Z MVJT:;K7Y-+W:%Y%G97Y8AA@KO/F"*;.%90M[W85MVS-;73'$7BC^]4EFJ.=M M:)Z%A?5]ALV;W/4\A+;6JMO1/L;)9;8>RH 3ICLU79;+\"05-I^T'304:BE4E4 M;FJ59C,CT0Z3J%[3&J\0TV8D6IU$U2HHNNW[/0>['LKNG5RK[!EH6<46HE"U=J/D1MYH]:ZB=K^S/R)ABL@T1O-G+T3Q%5K6J.TT6V"/W \)%*,9_)3W+(; M*];A6:_S&EQ6JV6=/KM,GW(C:Y;;9?JT&EF,NLOTJ;]>L^GN1D!I/J@4Q;FW M86"T.093 [^8Q<1[Q+"#GLDV_&FGK<1XZB#R=\@6>"K\E@4K,R++&I%2L?D2"?K M+_>3\_MC$P"P\.0J4V'G40P?7MP["0T0OGSR+'=-#(&?6YZ[C-6@"=DTAF8C MW#H#[#1G; KB[<*JI&(U8"MMK5%K:?5&;0[ R\K56R$T8\B?C"%K6JE>TYW0\9\CW2I3S=Y0N)STT^<(;G1LQF?G7D[ M1T(NG#:D\(]],&1Z92E)GE=RG/?JQ@Y)W.!I0"\[\FWU5?RPZ.DRG8UZS"75 M\K91E!V EQT;]F,C^6<^-JQ96_?8,.K)$RET_ 5/G'^@)IY_/8VT]W>J5;59 MT9J-U+;7[.RPC6*Y!CS>:*5J?5O \HZ5A/=._K+=;_CY8ITZW*?FNVCQKC:: M6KF>'6:RHK!4*EJUG.I>W@D)V?)^)KDOF'H>2]NFGY/6M;I6:V62LB+VFFVM MF>[-V@E)V88MD>(A2L!#\%>9ZWUTO>^!?21\.G_\+HA>+9=G->1E(K,<]FH- M4-Q;.Z1M5LIW$PG?LVB6^:G$I<-).7C!MQTQ070A# M%Q@*FO+ >F.?;+I[W MN8D,YC,S=ND#-\B9[=*A1CJ?3[<^X9\W,(]T2\D5=;]A@OHC'3E')%PYN64F M55\&WS(PQU]/#$1 $8^W'OZGQ_6Q;C+_J:C;H^/#K]M'?Z/<))52M= 2G_'> M\F13F>IM<_(5,SA]'2X^=0>V3VZHZUM@G[8^W1T%;B%W 5RR7H-'%5_^A^(R M';7*5^/12KE2:)1*A7*[5$E/%BG-^?R5>"2Z^:]"@7SFS#0^ =D&[ @@^AXP M2V>?2.V(7#M"_C^12^KYI% (+5SWXL_)027H^'V?%.RB8/-<$F\&D).2&UL M4$L! A0#% @ 6,M,C R,C X,#1?<')E+GAM;%!+ 0(4 Q0 ( '(X!%6<1@O 0!8 M ,-[ 2 " N80; #,X %@ @ $]. =&TR I,C(R-#@W9#%?97@Y.2TQ+FAT;5!+!08 !@ & (P! #U4P ! end